Literature DB >> 1703354

Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506.

A B Jain1, J J Fung, S Todo, M Alessiani, S Takaya, K Abu-Elmagd, A Tzakis, T E Starzl.   

Abstract

FK 506 therapy with low doses of steroids was adequate to control rejection in most liver recipients. Rejection episodes were readily reversed with single IV doses of methylprednisone or hydrocortisone. Short courses of OKT3 (3 to 5 days 5-10 mL) controlled severe rejections. The rate of retransplantation directly due to rejection was low (1.6%). There was a limited need for steroids either early or out to 6 to 12 months.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1703354      PMCID： PMC2967371     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


  10 in total

1.  Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.

Authors:  J J Fung; S Todo; A Jain; J McCauley; M Alessiani; C Scotti; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

2.  FK 506 dosage in human organ transplantation.

Authors:  A B Jain; J J Fung; R Venkataramanan; S Todo; M Alessiani; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

3.  Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine.

Authors:  N Murase; S Todo; P H Lee; H S Lai; F Chapman; M A Nalesnik; L Makowka; T E Starzl
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

4.  FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.

Authors:  T Kino; H Hatanaka; S Miyata; N Inamura; M Nishiyama; T Yajima; T Goto; M Okuhara; M Kohsaka; H Aoki
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

5.  Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat.

Authors:  T Ochiai; K Nakajima; M Nagata; T Suzuki; T Asano; T Uematsu; T Goto; S Hori; T Kenmochi; T Nakagoori
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

6.  FK 506 for liver, kidney, and pancreas transplantation.

Authors:  T E Starzl; S Todo; J Fung; A J Demetris; R Venkataramman; A Jain
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

7.  IN VITRO IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 ON HUMAN T LYMPHOCYTE ALLOACTIVATION.

Authors:  A Zeevi; R Duquesnoy; G Eiras; S Todo; L Makowka; T Starzl
Journal:  Surg Res Commun       Date:  1987

8.  Liver, kidney, and thoracic organ transplantation under FK 506.

Authors:  S Todo; J J Fung; T E Starzl; A Tzakis; A J Demetris; R Kormos; A Jain; M Alessiani; S Takaya; R Shapiro
Journal:  Ann Surg       Date:  1990-09       Impact factor: 12.969

9.  Kidney transplantation under FK 506.

Authors:  T E Starzl; J Fung; M Jordan; R Shapiro; A Tzakis; J McCauley; J Johnston; Y Iwaki; A Jain; M Alessiani
Journal:  JAMA       Date:  1990-07-04       Impact factor: 56.272

10.  Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction.

Authors:  S Todo; Y Ueda; J A Demetris; O Imventarza; M Nalesnik; R Venkataramanan; L Makowka; T E Starzl
Journal:  Surgery       Date:  1988-08       Impact factor: 3.982
  10 in total
  24 in total

1.  Pediatric liver transplantation in 808 consecutive children: 20-years experience from a single center.

Authors:  A Jain; G Mazariegos; R Kashyap; B Kosmach-Park; T E Starzl; J J Fung; J Reyes
Journal:  Transplant Proc       Date:  2002-08       Impact factor: 1.066

2.  The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation.

Authors:  J J Fung; M Eliasziw; S Todo; A Jain; A J Demetris; J P McMichael; T E Starzl; P Meier; A Donner
Journal:  J Am Coll Surg       Date:  1996-08       Impact factor: 6.113

3.  Neurologic complications of FK 506.

Authors:  B H Eidelman; K Abu-Elmagd; J Wilson; J J Fung; M Alessiani; A Jain; S Takaya; S N Todo; A Tzakis; D Van Thiel
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

4.  Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant.

Authors:  A B Jain; S Todo; J J Fung; R Venkataramanan; R Day; J Bryant; K M Abu-Elmagd; M Alessiani; S Takaya; A Tzakis
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

5.  The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver.

Authors:  K Abu-Elmagd; J J Fung; M Alessiani; A Jain; R Venkataramanan; V S Warty; S Takaya; S Todo; W D Shannon; T E Starzl
Journal:  Transplantation       Date:  1991-07       Impact factor: 4.939

6.  Long-term survival after liver transplantation in 4,000 consecutive patients at a single center.

Authors:  A Jain; J Reyes; R Kashyap; S F Dodson; A J Demetris; K Ruppert; K Abu-Elmagd; W Marsh; J Madariaga; G Mazariegos; D Geller; C A Bonham; T Gayowski; T Cacciarelli; P Fontes; T E Starzl; J J Fung
Journal:  Ann Surg       Date:  2000-10       Impact factor: 12.969

7.  One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events.

Authors:  A B Jain; J J Fung; S Todo; J Reyes; R Selby; W Irish; H Doyle; K Abu-Elmagd; A Casavilla; B Nour
Journal:  Transplant Proc       Date:  1995-02       Impact factor: 1.066

8.  Monitoring and treatment of intestinal allograft rejection in humans.

Authors:  K M Abu-Elmagd; A Tzakis; S Todo; J Reyes; J Fung; K Nakamura; H Wright; H Furukawa; J Demetris; D H Van Thiel
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

9.  FK 506 in small bowel transplant recipients: pharmacokinetics and dosing.

Authors:  A Jain; R Venkataramanan; J Lever; V Warty; K Abu-Elmagd; H Furukawa; J Reyes; B Nour; A Asrian; A Tzakis
Journal:  Transplant Proc       Date:  1994-06       Impact factor: 1.066

10.  Immunosuppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF)-kappa(B). Implications for FK506 nephropathy.

Authors:  K Muraoka; K Fujimoto; X Sun; K Yoshioka; K Shimizu; M Yagi; H Bose; I Miyazaki; K Yamamoto
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.